Three studies [18,19] have published significantly improved survival and responses to platinum-based chemotherapy for BRCA-positive pancreatic cancers; therefore, gemcitabine plus cisplatin is recommended by the NCCN for UPC with BRCA1/2 or PABL2 mutation. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.